Latest news with #MedicusPharma
Malay Mail
22-05-2025
- Business
- Malay Mail
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE [email protected] [email protected] Cautionary Notice on Forward-Looking Statements Philadelphia, Pennsylvania - Newsfile Corp. - May 22, 2025 - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The company also announced expanding clinical trial sites in April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (""), a UK-based late clinical stage biotech company, developinga next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged Bonner, President(610) 636-0184Anna Baran-Djokovic, SVP Investor Relations(305) 615-9162Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (""), a UK-based late clinical stage biotech company, developinga next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. The issuer is solely responsible for the content of this announcement.
Associated Press
28-03-2025
- Business
- Associated Press
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out
The market's focus is narrow, but step outside the spotlight and you'll find where real momentum is building LONDON, United Kingdom, March 27, 2025 (EZ Newswire) -- ValueTheMarkets, a trusted resource for retail investors offering financial news, in-depth analysis, and investment insights, today shared insights into small-cap biotech stocks. In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly's (NYSE: LLY) respectable 9.55% gain and leaving Novo's -15.9% slide far behind. But it's not chasing blockbuster weight loss drugs—it's targeting a radically different frontier: non-invasive skin cancer treatment. The market's attention remains fixated on obesity drugs, but that trade is looking tired. Novo's drop reflects valuation fatigue. Lilly's gains are narrowing. Small-cap biotech moves fast when the story clicks. Medicus Pharma Ltd (NASDAQ: MDCX) is developing the SkinJect D-MNA patch for basal cell carcinoma (BCC) (1), a proprietary microneedle array that is a non-invasive, painless, and cost-effective alternative to Mohs surgery, the current standard of care. A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor's office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average (2). Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500) (3). Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4). The deal could be worth up to $2 billion, with $200 million paid upfront and the rest tied to performance milestones. Novo will also pay royalties if the drug sells well outside of China. United Laboratories retains rights in China, Hong Kong, Macau, and Taiwan, while Novo Nordisk holds exclusive rights elsewhere. Novo Nordisk's new weight-loss drug CagriSema showed 15.7% weight loss in patients with Type 2 diabetes in its most recent trial (5). While effective, the results came in below some analyst expectations, contributing to a negative market reaction. Eli Lilly (NYSE: LLY) is set to release key results this year from late-stage trials of its experimental weight-loss pill, orforglipron (6). These results are highly anticipated, as the once-daily pill could offer a needle-free option for treating obesity and diabetes. If successful, it may expand access for patients globally and ease supply issues affecting injectable treatments. The pill could also strengthen Eli Lilly's lead in the fast-growing weight-loss drug market as competitors rush to catch up. Meanwhile, Lilly has recently expanded its cancer drug pipeline by acquiring an experimental PI3K inhibitor from Scorpion Therapeutics (7). This drug, STX-678, targets PI3Ka mutations common in breast, gynecological, and head and neck cancers. Both Novo and Lilly are now advancing next-generation GLP-1-based therapies, including Novo's newly licensed UBT251 and Lilly's injectable retatrutide. Early data from UBT251 show promising double-digit weight loss over a short treatment window, though Lilly's drug has demonstrated even greater efficacy over longer trials. While Lilly continues to deepen its presence in both obesity and oncology, Novo remains more narrowly focused, with only a limited footprint beyond its core metabolic disease portfolio. The weight-loss space is increasingly defined by heavyweight competition—and fewer fresh angles. In markets weighed down by macro fatigue and sector rotation, attention gravitates toward headline-grabbing giants, and small caps often get overlooked—until they don't. While the biggest names fight to meet sky-high expectations, smaller players can deliver outsized returns simply by executing well on underappreciated ideas. These companies don't need to dominate a $100 billion category to reward investors—they just need to solve a real problem, move quickly, and fly under the radar long enough for the story to catch up to the fundamentals. That's how some of this year's most surprising outperformers have pulled well ahead of the S&P 500, which remains down nearly 2% year-to-date. While broader markets churn, select small-cap biotech names are showing that meaningful innovation still gets rewarded. As the weight-loss drug trade gets crowded and priced in, this could be the moment to look beyond the usual suspects. Discover more about . About Digitonic Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit About ValueTheMarkets ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit Sources: Medicus Pharma Investor Presentation, Q1 2025. Accessed February 2025. National Library of Medicine. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. Analyst Coverage from Maxim Group, 17 Dec 2024, and Brookline Capital Markets, 23 Dec 2024. Both reports were supplied by Medicus Pharma in February 2025. (Note: Analyst targets are based on projections and assumptions that may not materialize.) GlobeNewswire. The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist. March 24, 2025. GlobeNewswire. Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial. March 10, 2025. CNBC. Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer. March 24, 2025. Lilly. Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program. January 13, 2025. IMPORTANT NOTICE AND DISCLAIMER PAID ADVERTISEMENT This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the 'Publisher') is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher's ability to provide unbiased information or opinion. CHANGES IN SHARE TRADING AND PRICE Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur. NO OFFER TO SELL OR BUY SECURITIES This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. INFORMATION Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company's CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views. NO FINANCIAL ADVICE The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual's financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. FORWARD LOOKING STATEMENTS This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company's actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company's operations; the size and growth of the market for the company's products and services; the company's ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company's business. INDEMNIFICATION/RELEASE OF LIABILITY By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions. TERMS OF USE AND DISCLAIMER By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here. If you do not agree to the Terms of Use, please contact to discontinue receiving future communications. INTELLECTUAL PROPERTY All trademarks used in this communication are the property of their respective trademark holders. Other than the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance. ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of has been paid for the production of this piece by the company or companies mentioned above. Media Contact
Reuters
27-03-2025
- Business
- Reuters
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out
LONDON, United Kingdom, March 27, 2025 (EZ Newswire) -- ValueTheMarkets, a trusted resource for retail investors offering financial news, in-depth analysis, and investment insights, today shared insights into small-cap biotech stocks. In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly's (NYSE: LLY) respectable 9.55% gain and leaving Novo's -15.9% slide far behind. But it's not chasing blockbuster weight loss drugs—it's targeting a radically different frontier: non-invasive skin cancer treatment. The market's attention remains fixated on obesity drugs, but that trade is looking tired. Novo's drop reflects valuation fatigue. Lilly's gains are narrowing. Small-cap biotech moves fast when the story clicks. Medicus Pharma Ltd (NASDAQ: MDCX) is developing the SkinJect D-MNA patch for basal cell carcinoma (BCC) (1), a proprietary microneedle array that is a non-invasive, painless, and cost-effective alternative to Mohs surgery, the current standard of care. A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor's office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average (2). Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500) (3). Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4). The deal could be worth up to $2 billion, with $200 million paid upfront and the rest tied to performance milestones. Novo will also pay royalties if the drug sells well outside of China. United Laboratories retains rights in China, Hong Kong, Macau, and Taiwan, while Novo Nordisk holds exclusive rights elsewhere. Novo Nordisk's new weight-loss drug CagriSema showed 15.7% weight loss in patients with Type 2 diabetes in its most recent trial (5). While effective, the results came in below some analyst expectations, contributing to a negative market reaction. Eli Lilly (NYSE: LLY) is set to release key results this year from late-stage trials of its experimental weight-loss pill, orforglipron (6). These results are highly anticipated, as the once-daily pill could offer a needle-free option for treating obesity and diabetes. If successful, it may expand access for patients globally and ease supply issues affecting injectable treatments. The pill could also strengthen Eli Lilly's lead in the fast-growing weight-loss drug market as competitors rush to catch up. Meanwhile, Lilly has recently expanded its cancer drug pipeline by acquiring an experimental PI3K inhibitor from Scorpion Therapeutics (7). This drug, STX-678, targets PI3Ka mutations common in breast, gynecological, and head and neck cancers. Both Novo and Lilly are now advancing next-generation GLP-1-based therapies, including Novo's newly licensed UBT251 and Lilly's injectable retatrutide. Early data from UBT251 show promising double-digit weight loss over a short treatment window, though Lilly's drug has demonstrated even greater efficacy over longer trials. While Lilly continues to deepen its presence in both obesity and oncology, Novo remains more narrowly focused, with only a limited footprint beyond its core metabolic disease portfolio. The weight-loss space is increasingly defined by heavyweight competition—and fewer fresh angles. In markets weighed down by macro fatigue and sector rotation, attention gravitates toward headline-grabbing giants, and small caps often get overlooked—until they don't. While the biggest names fight to meet sky-high expectations, smaller players can deliver outsized returns simply by executing well on underappreciated ideas. These companies don't need to dominate a $100 billion category to reward investors—they just need to solve a real problem, move quickly, and fly under the radar long enough for the story to catch up to the fundamentals. That's how some of this year's most surprising outperformers have pulled well ahead of the S&P 500, which remains down nearly 2% year-to-date. While broader markets churn, select small-cap biotech names are showing that meaningful innovation still gets rewarded. As the weight-loss drug trade gets crowded and priced in, this could be the moment to look beyond the usual suspects. Discover more about Medicus Pharma and its plans to commercialize its non-invasive SkinJect patch for BCC. About Digitonic Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit About ValueTheMarkets ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit Sources: IMPORTANT NOTICE AND DISCLAIMER PAID ADVERTISEMENT This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the 'Publisher') is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher's ability to provide unbiased information or opinion. CHANGES IN SHARE TRADING AND PRICE Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur. NO OFFER TO SELL OR BUY SECURITIES This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. INFORMATION Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company's CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views. NO FINANCIAL ADVICE The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual's financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. FORWARD LOOKING STATEMENTS This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company's actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company's operations; the size and growth of the market for the company's products and services; the company's ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company's business. INDEMNIFICATION/RELEASE OF LIABILITY By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions. TERMS OF USE AND DISCLAIMER By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here. If you do not agree to the Terms of Use, please contact to discontinue receiving future communications. INTELLECTUAL PROPERTY All trademarks used in this communication are the property of their respective trademark holders. Other than the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance. ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of has been paid for the production of this piece by the company or companies mentioned above. Media Contact ### SOURCE: Digitonic
